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NRF2 PATHWAY AND THE REDUCTION OF OXIDATIVE STRESS
Stephanie Jacobs Uselman PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND  58202-9037
ABSTRACT
INTRODUCTION 
• Cellular damage induced by oxidative stress can lead to vulnerability toward 
cellular aging and predispose cells to disease processes. 
• Cells respond to oxidative stress by increasing their endogenous antioxidant 
capacity, thereby decreasing the effects of reactive oxygen species. 
• This process is modulated by the nuclear factor erythroid 2-related factor 
(Nrf2) – Keap 1 pathway. 
• Nrf2 upregulates a series of phase II detoxification and antioxidant genes, 
aids in cell survival, is anti-inflammatory, and assists in energy metabolism.
•
• Prevention of oxidative stress by phytochemicals has been studied as an 
approach to treatment of several diseases. 
RESEARCH QUESTION 
LITERATURE REVIEW 
APPLICABILITY TO CLINICAL 
PRACTICE 
DISCUSSION 
• Nelson et al. (2005), Quereshi et al. (2010), Burnham et al. (2012), and 
Reuland et al. (2013) conducted studies that resulted in decreased TBARS.
• Liu et al. (2009, Donovan et al. (2012), and Reuland et al. (2013) 
conducted studies that resulted in increased levels of antioxidants.
• Robbins et al. (2010), and Reuland et al. (2013) conducted studies that 
resulted in suppression of cellular apoptosis.
• Lie et al. (2009) conducted studies that resulted in decreased tumor 
incidence. 
• Nelson et al. (2005), Liu et al. (2009), Quereshi et al. (2010), Robbins et al. 
(2010), Robbins et al. (2010), Burnham et al, (2010), Donovan et al. 
(2012), and Reuland et al. (2013) conducted studies that resulted in 
decreased levels of cellular oxidative stress. 
Oxidative stress has been linked to cellular damage initiating disease processes 
such as cardiovascular disease, diabetes, and cancer. The Nuclear factor 
erythroid-derived 2 (Nrf2) pathway (Figure 1) aids in age-related cellular 
decline. The purpose of this study was to define the relationship between 
Protandim, its activation of the Nrf2 pathway, and decline in oxidative stress and 
cellular damage. The literature review included journal articles obtained from 
PubMed, Google scholar, and Cochrane review within the past 5-10 years, and 
contained both animal and human studies. The methods used in the animal 
studies included ANOVA, the standardized t-test, and the Neuman-Keuls post-
test. P<0.05 was considered statistically significant. The human study included 
healthy participants, both male and female, age 29-78 with or without a specific 
medical diagnosis. Statistical analysis was based on the standardized t-test with 
a value of p<0.05 considered statistically significant. Liu et al. (2009) conducted 
a study investigating Protandim’s ability to suppress cancer tumor formation. 
Tumor incidence declined by 33% and multiplicity of skin tumors by 57% with 
p = 0.003. Superoxide dismutase increased 35%, catalase 58%, and manganese 
superoxide dismutase 21%. In 2013, Reuland et al. conducted a study to 
determine if Protandim could activate the Nrf2 pathway and induce antioxidant 
enzymes, thereby protecting cardiomyocytes from apoptosis. Results indicated 
that treated cardiomyocytes showed increased levels of Nrf2 nuclear 
accumulation, activation of endogenous antioxidant enzymes, and protection 
against cell targeted oxidative stress (p<0.05). Quereshi et al. (2010) completed 
a study to delineate if Protandim decreased oxidative stress through the Nrf2 
pathway. After six months of supplementation, TBARS decreased by 48% 
(p=.006), and plasma osteopontin decreased by 57% (p=.018). In 2005, Nelson 
et al. conducted a study to determine if Protandim decreased cellular damage. 
After 30 days of supplementation, TBARS declined by 40% (p =0.0001), at 120 
days, TBARS declined by 40-54% (p =0.002), and superoxide dismutase and 
catalase increased by 30% and 54% respectively. The results from studies 
indicate that Protandim’s activation of the Nrf2 pathway increased endogenous 
antioxidant availability, resulting in decreased oxidative stress and age related 
cellular damage. 
In adult patients, does a diet containing the supplement Protandim 
compared to a diet not containing the supplement Protandim, lower 
overall cellular oxidative stress?
• Nelson et al. (2005) found that Protandim decreased cellular 
damage. After 30 days of supplementation, TBARS declined 40% 
(p =0.0001), at 120 days, TBARS declined 40-54% (p 
=0.002).Superoxide dismutase and catalase increased 30% and 
54% respectively (Figure 3). 
• Liu et al. (2009) found that skin tumor incidence declined 33% 
and multiplicity of tumors declined by 57% (p=0.003). Superoxide 
dismutase increased 35%, catalase 58%, and manganese 
superoxide dismutase 20%. 
• Robbins et al. (2010) concluded that Protandim suppressed 
DMBA/TPA induced cellular apoptosis. 
• Quereshi et al. (2010) found that Protandim decreased oxidative 
stress through the Nrf2 pathway. After six months of 
supplementation, TBARS decreased 48% (p=.006), and plasma 
osteopontin decreased 57% (p=.018) (Figure 2.)
• Burnham et al. (2012) found that treatment with Protandim 
decreased TBARS (p<0.01). 
• Donovan et al. (2012) found HCAEC treated with Protandim 
induced heme oxygenase (778% of control +/- 82.25 (p < 0.01), 
superoxide dismutase (125.9% of control +/- 6.05 (p < 0.01), 
NQO1 (126% of control +/- 6.5 (p < 0.01), and glutathione 
reductase (119.5% of control +/- 7.00 (p < 0.05).
• Mitsuishi, Motohashi, & Yamamoto (2012) outlined the 
pathophysiology of the Keap1-Nrf2 pathway.
• Reuland et al. (2013) found that Protandim treated cardiomyocytes 
showed increased levels of Nrf2 nuclear accumulation, activation 
of endogenous antioxidant enzymes, decreased cellular apoptosis, 
and protection against cell targeted oxidative stress (p<0.05). 
• Cellular insult from reactive oxygen species is unavoidable. They are responsible 
for damage to cell membranes, DNA, and tissues. This damage can lead to 
premature aging and initiation of disease processes such as cancer, heart disease, 
neurodegenerative disease, and muscular disorders (Figure 4). 
• Endogenous antioxidants are mediated through the Nrf2 pathway. Nrf2 also plays a 
role in regulation of survival genes. 
• Scientific evidence has shown that Protandim induces the Nrf2 pathway, increases 
endogenous antioxidant production and provides cellular protection from damage 
due to oxidative insults.
STATEMENT OF THE PROBLEM
Studies are needed to show whether or not the nutritional supplement Protandim 
is effective in lowering overall cellular oxidative stress thereby decreasing risk 
for disease process.
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Figure 1. Keap1-Nrf2 Pathway. Under normal conditions, Nrf2 is 
ubiquitinated through Keap1 and degraded. Exposure to oxidative stress 
causes inactivation of Keap1. Nrf2 accumulates in the nucleus and 
activates multiple cytoprotective genes (Mitsuishi, Y., Motohashi, H., & 
Yamamoto, M. (2012). 
Keap1-Nrf2 Pathway 
Figure 2. Plasma TBARS: Protandim vs. Control Group. Diets containing 
Protandim show a 48% decrease in plasma TBARS; 0.92 nmol/mg in controls (n
= 9) versus 0.48 nmol/mg in Protandim® group (n = 12; p = .006) (Quereshi et al. 
(2010).
Figure 2. Inhibition of Lipid Peroxidation (TBARS) by Protandim. Human 
subjects before supplementation with Protandim showed an age-dependent 
increase in TBARS. The levels of TBARS dropped an average of 40% 
(p<0.0001) after 30 days of Protandim supplementation, and the age-related 
increase in TBARS virtually disappeared. (Nelson et al. (2005).
Figure 4. Oxidative Stress and Disease. Oxidative stress is a state is which free radicals 
overwhelms the body’s antioxidant defense mechanism. This process has been implicated in 
the development of many diseases (Neurogenol, (2010). 
